See more : Public Joint Stock Company Multisistema (MSST.ME) Income Statement Analysis – Financial Results
Complete financial analysis of Brii Biosciences Limited (BRIBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Brii Biosciences Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Getchell Gold Corp. (GTCH.CN) Income Statement Analysis – Financial Results
- Wildcat Resources Limited (WC8.AX) Income Statement Analysis – Financial Results
- BAUER Aktiengesellschaft (B5A.DE) Income Statement Analysis – Financial Results
- Maps S.p.A. (MAPS.MI) Income Statement Analysis – Financial Results
- Prosper One International Holdings Company Limited (1470.HK) Income Statement Analysis – Financial Results
Brii Biosciences Limited (BRIBF)
About Brii Biosciences Limited
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 617.00K | 51.63M | 92.54M | 82.22M | 20.20M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 617.00K | 51.63M | 92.54M | 82.22M | 20.20M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 402.71M | 440.63M | 494.62M | 875.80M | 83.79M |
| General & Administrative | 55.69M | 53.47M | 79.31M | 49.84M | 22.55M |
| Selling & Marketing | 1.42M | 26.86M | 0.00 | 0.00 | 0.00 |
| SG&A | 57.10M | 80.33M | 79.31M | 49.84M | 22.55M |
| Other Expenses | -459.19M | 44.85M | 68.69M | -13.75M | 20.59M |
| Operating Expenses | 617.00K | 565.81M | 642.61M | 911.88M | 126.92M |
| Cost & Expenses | 600.62M | 565.81M | 642.61M | 911.88M | 126.92M |
| Interest Income | 108.02M | 37.20M | 6.49M | 2.41M | 143.00K |
| Interest Expense | 494.00K | 851.00K | 1.18M | 1.67M | 1.11M |
| Depreciation & Amortization | 15.67M | 17.03M | 7.68M | 6.19M | 2.81M |
| EBITDA | -168.20M | -503.58M | -602.80M | -890.79M | -124.11M |
| EBITDA Ratio | -27,261.26% | -975.45% | -4,557.33% | -1,523.53% | -2,563.48% |
| Operating Income | -544.30M | -520.62M | -4.23B | -1.27B | -525.21M |
| Operating Income Ratio | -88,217.34% | -1,008.44% | -4,575.98% | -1,540.81% | -2,600.58% |
| Total Other Income/Expenses | 359.93M | 24.41M | -3.58B | -386.54M | -394.11M |
| Income Before Tax | -184.37M | -489.78M | -4.19B | -1.28B | -521.03M |
| Income Before Tax Ratio | -29,881.69% | -948.71% | -4,528.85% | -1,561.11% | -2,579.86% |
| Income Tax Expense | 0.00 | -37.16M | -70.86M | -77.22M | -4.19M |
| Net Income | -174.83M | -452.63M | -4.12B | -1.21B | -516.84M |
| Net Income Ratio | -28,335.33% | -876.74% | -4,452.28% | -1,467.18% | -2,559.14% |
| EPS | -0.24 | -0.63 | -9.38 | -1.71 | -0.73 |
| EPS Diluted | -0.24 | -0.63 | -9.38 | -1.71 | -0.73 |
| Weighted Avg Shares Out | 728.10M | 723.48M | 439.05M | 706.20M | 706.20M |
| Weighted Avg Shares Out (Dil) | 728.10M | 723.48M | 439.05M | 706.20M | 706.20M |
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results
Source: https://incomestatements.info
Category: Stock Reports